This randomised controlled trial compared three analgesia regimens following primary unilateral total knee joint replacement: continuous femoral nerve block (CFNB), intrathecal morphine (ITM), and both. The primary outcome was pain ratings over the first 24 hours. Secondary outcomes included morphine consumption, nausea, pruritus and sedation ratings, oxygen saturation (SpO 2 ) ratings, and ability to mobilise postoperatively. All patients received a spinal anaesthetic and a postoperative patientcontrolled morphine pump. Patients were randomised to receive CFNB, ITM, or both. In patients with no CFNB, the use of ITM was blinded. Eighty-one patients were randomised and there were no withdrawals. At 24 hours, the ITM-only group had higher pain ratings than either of the other groups (P=0.04 versus CFNB, P=0.01 versus combination). In the 18 to 24-hour period, the ITM group used more morphine than either of the other groups. There were no statistically significant differences in pain ratings or morphine consumption at earlier time intervals. The ITM group were less likely to be able to sit out of bed on day one. Patients who received ITM were more likely to have pruritus. There were no statistically significant differences in nausea, SpO 2 or sedation ratings. This study showed that a CFNB resulted in reduced pain and was also associated with less morphine consumption and improved mobilisation at 24 hours compared to ITM. This study did not show any statistically significant differences between CFNB alone and CFNB+ITM.
Pain following total knee joint replacement (TKJR) can be severe and many analgesic regimens have been used to improve both the quality of analgesia and early mobilisation. For TKJR, continuous femoral nerve blocks (CFNBs) provide improved analgesia compared with systemic opioids [1] [2] [3] , and equivalent or better analgesia, with improved side-effect profiles and functional recovery, than epidural analgesia [4] [5] [6] . The knee is innervated by the femoral nerve, however the sciatic nerve also contributes, therefore CFNB should be utilised as only one component of multimodal analgesia. Studies into the usefulness of sciatic 7, 8 or obturator [9] [10] [11] nerve blocks have yielded conflicting results. Supplementary analgesia can include oral or intravenous (IV) adjuvant analgesics, sciatic nerve blockade or intrathecal morphine (ITM). ITM confers superior analgesia compared to IV patientcontrolled analgesia (PCA) with morphine, but is associated with side-effects including nausea, pruritus and respiratory depression [12] [13] [14] [15] . ITM may obviate the need for a CFNB. For patients receiving a spinal anaesthetic, ITM adds negligible anaesthetic preparation time, whereas a commonly utilised adjuvant, sciatic nerve blockade, requires further time to prepare the patient for surgery.
The aim of this prospective, blinded, randomised controlled trial was to compare analgesia, side-effect profiles and functional recovery following TKJR and three analgesic regimens: CFNB alone, ITM alone, and combined CFNB and ITM.
Methods
Following approval by the Human Research Ethics Committee of St Vincent's Hospital, Melbourne (HREC Ref No.: 148/04), and clinical trial registration (ACTRN12606000421538), patients scheduled to undergo primary TKJR were invited to participate in this study and written informed consent was obtained from all recruited patients. Exclusion criteria were inability to give informed consent, inability to comprehend instructions regarding an IV PCA device or a pain rating ruler and contraindications to femoral nerve blockade, spinal anaesthesia or any study drug.
In addition to patient and surgical characteristics, data collected included factors with the potential to increase the likelihood of postoperative nausea and vomiting or hypoxia. These were a past history of motion sickness or postoperative nausea and vomiting, smoking status, chronic obstructive pulmonary disease, or asthma.
Patients were randomised on the day of surgery prior to the pre-anaesthesia consultation using computer-generated, permuted block randomisation into one of three groups: group CFNB received a CFNB; group ITM received ITM and group COMB received the combination of the two techniques. Randomisation envelopes were opaque, consisting of a small envelope inside a larger one. As well as the small envelope, the outer envelope contained a slip indicating if the patient was to receive a CFNB. The inner randomisation envelope was opened by an investigator not involved in the patient's anaesthetic care or in postoperative data collection. This contained a slip indicating if the patient was to receive ITM.
All patients received oral paracetamol 1 g and celecoxib 200 mg one hour preoperatively. Patients received sedation with IV midazolam at the discretion of the anaesthetist. Patients in the CFNB and COMB groups had a femoral nerve catheter inserted by a consultant anaesthetist using a Contiplex® 18-gauge Tuohy Continuous Nerve Block Set (B.Braun, Melsungen, Germany). The needle puncture site was just lateral to the femoral artery, caudal to the inguinal ligament but cephalad to the groin crease. Needle placement was guided using a peripheral nerve stimulator (Stimuplex®, HNS11, B.Braun, Melsungen, Germany), with a quadriceps twitch at <0.5 mA (pulse width 300 ms, frequency 2 Hz) considered an acceptable response. The catheter was then threaded to 5 cm beyond the needle tip before being tunnelled inferolaterally onto the thigh, distal to the groin crease. A loading dose of 20 ml of 0.75% ropivacaine (Astra Zeneca Pty Ltd., North Ryde, New South Wales), plus adrenaline 5 µg/ml, was then injected via the catheter.
All patients received a spinal injection of 0.5% bupivacaine 3.5 ml while the ITM and COMB groups also received 175 µg (3.5 ml of 50 µg/ml) of ITM. A sterile 20 ml bottle of 0.5% bupivacaine (Pfizer, New York City, NY, USA) was opened onto the anaesthetist's sterile field. The investigator holding the ITM randomisation slip then injected 0.1 ml of study drug into the vial of bupivacaine, maintaining sterility. For the ITM and COMB groups, the study drug was 0.1 ml (1 mg) of preservative-free morphine, resulting in a morphine concentration of 50 µg/ml. For the CFNB group, the study drug was 0.1 ml of 0.5% bupivacaine, resulting in no change in the bottle's contents.
The use of CFNBs was not blinded. For ethical reasons, there was no placebo group. Therefore, patients without CFNB all received ITM. Patients with a CFNB may or may not have received ITM. This part of the use of ITM was kept blinded with respect to the patient, all clinical staff (including the surgeon, anaesthetist, nurses, and physiotherapists) and also the investigators collecting postoperative data.
All patients received a postoperative PCA pump delivering IV morphine. The pump was connected to the patient at the time of the spinal injection and the clock on the pump was used as the timer for postoperative time intervals. Therefore, all postoperative time intervals are taken from the time of the spinal injection.
Intraoperatively, an infusion of 0.2% ropivacaine at 12 ml/ hour via the femoral catheter was commenced within 20 minutes of the spinal injection. Patients were sedated at the discretion of the treating anaesthetist with midazolam and/or propofol. All patients received IV dexamethasone 8 mg at the start of the case and IV tropisetron 2 mg at the end.
Postoperatively, all patients received oral paracetamol 1 g qid and celecoxib 200 mg bd. Nausea was treated with IV tropisetron 2 mg and, if this was ineffective, metoclopramide 20 mg. The PCA device delivered 1 mg boluses of morphine with a five-minute lockout and no background infusion. The CFNBs were run at 8 to 14 ml/hour until the morning of postoperative day (POD) two. The initial infusion rate and any subsequent changes were made at the discretion of the Acute Pain Service and the cumulative local anaesthetic dose was recorded. At this time, the CFNBs and morphine PCAs were ceased and oral oxycodone prn was prescribed.
All patients were visited at 6, 12, 18 and 24 hours postspinal injection. Primary endpoints were the pain ratings (0 to 100 mm) at rest at these timepoints. These were recorded using a proprietary ruler with a sliding pointer (Naropin® pain ruler, AstraZeneca, London, United Kingdom) with six anchor points over 10 cm on the side used by the patient with simple written descriptors and numeric ratings at 0 ('no hurt'), 2, 4, 6, 8 and 10 cm ('hurts worst'). A 100 mm scale on the reverse side was used to record the pain ratings, thus allowing for ratings falling in-between anchor points to be recorded as well. Daytime assessments were made by the research nurse, while those during the night were made by anaesthetic registrars who had received instruction from the research nurse. Secondary endpoints were the postoperative morphine consumption for the six-hour intervals preceding each of these timepoints. Sensory block was assessed as temperature discrimination to ice over the mid-thigh (femoral nerve) and medial malleolus (saphenous nerve), and was assessed in both the operative and non-operative lower limbs. The presence of nausea or pruritus was documented using a four-point scale (0-none; 1-mild, not requiring treatment; 2-responded to treatment; 3-persisted despite treatment). Sedation was assessed using a five-point scale (0-fully alert; 1-mildly drowsy; 2-moderately drowsy, easily rousable; 3-very drowsy, but rousable; 4-unrousable). The patients' oxygen saturations (SpO 2 ) were documented, in addition to whether or not supplemental oxygen was being delivered. On POD one, the physiotherapists documented the degree of knee flexion (active, active assisted and passive) and the pain ratings during these manoeuvres. Active assisted range of motion was also assessed on PODs two and three. The ability of the patient to sit out of bed on POD one and walk with crutches on POD three was documented.
Sample size was calculated based on an expected pain score at rest at 24 hours of 25 mm (standard deviation 13 mm) in the CFNB group (St Vincent's Hospital Melbourne Acute Pain Service data). To detect a 40% reduction in the COMB group, with a β value of 0.2 and an α value of 0.017 (allowing for three inter-group comparisons), 25 patients were required in each group. To allow for drop-outs and protocol violations, 81 patients were recruited. Statistical analysis was performed using Stata version 11 (StataCorp, College Station, TX, USA). Parametric data were compared using Student's t-test or analysis of variance. Non-parametric data were compared using a Mann-Whitney U test, Kruskall-Wallis test or Fisher's exact test as appropriate. Bonferroni's correction was used for multiple comparisons. All assessments were done on an intention-to-treat basis. Data are expressed as mean (standard deviation) or median (interquartile range) for normally distributed and skewed data respectively.
Results
Eighty-one patients were recruited (COMB n=26; CFNB n=28; ITM n=27). There were no withdrawals after randomisation. Demographic details are shown in the Table 1 . There were no statistically significant differences between groups.
The CFNBs were performed by 18 different consultant anaesthetists and the surgery by 13 different consultant surgeons. Figure 1 . There were no significant differences between groups at 6, 12 or 18 hours but at 24 hours a difference existed (Kruskall-Wallis with Bonferroni's correction: six hours P=0.53, 12 hours P=0.81, 18 hours P=0.56, 24 hours P=0.03). Pairwise analysis revealed that at 24 hours, the ITM group had higher pain ratings than either the CFNB or COMB groups (Wilcoxon rank-sum P=0.04 and 0.01, respectively). No difference existed between the CFNB and COMB groups (P=0.66).
Morphine consumption during different time intervals is depicted in Figure 2 . There were no significant differences between groups in the periods 0 to 6 hours, 6 to 12 hours or 12 to 18 hours, but a difference existed in the 18 to 24 hour period (0 to 6 hours P=0.77, 6 to 12 hours P=0.144, 12 to 18 hours P=0.174, 18 to 24 hours P=0.004). Pairwise analysis for the 18 to 24 hour period showed that the ITM group used more morphine than either the CFNB or COMB groups (Wilcoxon rank sum P=0.003 and P=0.006, respectively). No statistically significant difference existed between the COMB and CFNB groups (P=0.85).
There was no significant difference between the COMB and CFNB groups in the average rate of ropivacaine 0.2% infused (11.6 versus 12.0 ml/hour, P=0.48).
At 24 hours, 83% of those patients who had received a CFNB had a sensory block over the mid-thigh. Sensory block was not demonstrated in the contralateral leg, nor in patients who had not received a CFNB. At 24 hours, patients with no sensory block despite having received a CFNB had reduced pain ratings compared to patients who had not received CFNB (median pain score 13 mm versus 37 mm, P=0.004). Amongst those who had received CFNB (CFNB or COMB groups), there was no difference in pain ratings between those who had a block to ice and those who did not (median pain rating 15 mm versus 13 mm, P=0.31).
Nausea ratings are depicted in Figure 3 . A comparison of the maximum nausea score across all time intervals revealed no difference between groups, P=0.75.
Pruritus ratings are depicted in Figure 4 . A comparison of the maximum pruritus score showed that the CFNB group had less pruritus than the COMB or ITM groups (P=0.003 and 0.015, respectively). No statistically significant difference existed between the COMB and ITM groups (P=0.49).
There was no statistically significant difference between groups in sedation ratings or SpO 2 at any timepoint.
There was no statistically significant difference between groups in the degree of knee flexion achieved with physiotherapy, nor in the pain ratings during range-ofmotion assessments. Patients with CFNB, either alone or in combination with ITM, were more likely to be able to sit out of bed on POD one ( Figure 5 ). The most common reason for a failure to sit out of bed on POD one was nausea (n=5 out of 11). Other reasons were pain, sensory and motor block, deep vein thrombosis, wound ooze, drowsiness and low blood pressure (one each). There was no statistically significant difference between groups on the likelihood of the patient to be able to walk with crutches on POD three. 
Discussion
This prospective, randomised, observer-blinded trial supports the efficacy of CFNB following TKJR, with median pain ratings for the patients with CFNB less than 20 mm for the first 24 hours. Patients without CFNB (the ITM group) had similar analgesia for the first 18 hours, but then higher pain ratings at 24 hours.
The combination of ITM 175 µg and CFNB did not result in improved analgesia over the first 24 hours compared to CFNB alone. There was, however, a trend at 12 hours to both lower pain ratings and lower morphine consumption in the combination group. These two observations raise the possibility of a benefit of the combination technique, which this study had insufficient power to find.
Interestingly, all groups reported lower pain ratings postoperatively compared to their preoperative baseline ratings. This may reflect the significant degree of preoperative pain associated with serious osteoarthritis and also the fact that postoperative assessments were done at rest, whereas the preoperative assessments were the patient's worst daily knee pain.
The use of CFNB was associated with an improved ability to sit out of bed on POD one. The most common reason for inability was nausea, at a time when patients without CFNB had a higher PCA morphine consumption. Our study was not powered to assess the impact of CFNB, including any morphine-sparing effect, on postoperative ambulation; however, this important landmark in the clinical pathway following TKJR would be a fruitful area for future research, including studies extending further into the postoperative period.
ITM was associated with increased side-effects, although these were not particularly troublesome. Doses of 300 to 500 µg have been associated with high rates of nausea, vomiting and pruritus 12, 13, 16 and dose-finding studies 14, 17 have suggested 200 µg as the best balance between efficacy and minimisation of side-effects. We used 175 µg to allow our standard dose of bupivacaine (3.5 ml) to be drawn from a 20 ml bottle to which 1 mg of morphine had been added. The side-effects related to ITM were mostly mild and treatable. The increase in nausea was only at the six-hour timepoint and only two patients (of the 54 who received ITM) had nausea that persisted despite treatment with tropisetron and metoclopramide. Pruritus was common in patients receiving ITM, ranging from 22 to 59% at the various timepoints; however, only one patient required naloxone. Despite the documented risk of delayed respiratory depression with ITM, ITM has been combined safely with IV PCA morphine [13] [14] [15] 18 . This study, albeit with a small sample, supported these findings, with no difference between groups in sedation rating or oxygen saturation and no patient becoming cyanosed or excessively sedated.
We used cold discrimination as a method of assessing technical block success. Eighty-three percent of patients who had received CFNB had a demonstrable block over the proximal anterior thigh. Interestingly, however, patients who had received CFNB and yet had no demonstrable block to ice still had better analgesia than those who had received no CFNB. Conversely, among those patients who had received CFNB, there was no difference in analgesia between those who had a block to ice and those who did not. These findings cast doubt on the validity of using sensation to ice as an indicator of block success.
A potential limitation of our study is the lack of ultrasound (US) guidance in the placement of CFNB. This study was commenced before US became routine for insertion of CFNB in our hospital. It is possible that our technical success may have improved with the use of US guidance and the use of US would make a study more applicable to other centres where US use is commonplace. Another limitation is the lack of blinding of the presence or otherwise of a CFNB. Due to the ethical difficulties with performing sham blocks, patients in the ITM-only group did not receive a groin puncture. This also had the effect of limiting the blinding of ITM to the CFNB and COMB groups, as the patients with no groin puncture must have received ITM. A further potential limitation is the number of different anaesthetists who performed the CFNBs, raising the possibility of operator variability. This is offset by the fact that all were consultant anaesthetists and the study was conducted in a major teaching hospital with departmental expertise in these techniques.
This study was limited to the techniques for CFNB and ITM. Other well-described techniques include periarticular infiltration of high volumes of local anaesthetic (local infiltration analgesia) and use of adjuvants such as tramadol, ketamine and gabapentinoids, which represent interesting areas for further research.
Conclusion
In summary, this randomised controlled trial supports the efficacy of CFNB following TKJR. ITM alone was associated with higher pain ratings and morphine consumption at 24 hours was also associated with more pruritus and a decreased ability to sit out of bed on POD one. As such, its sole use following TKJR is not as well supported as CFNB. We did not demonstrate a significant benefit of combining CFNB and ITM over CFNB alone, but the observed trend towards both lower pain ratings and lower morphine consumption in the combination group warrants further investigation.
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